Citations

Clear

9383 citation(s) found for "Thomas, PS".

Midterm Outcomes in a Pooled Cohort of Harmony Transcatheter Pulmonary Valve Recipients
Morray, Brian H. , Gillespie, Matthew J. , Cheatham, John P. , Salavitabar, Arash , Peng, Lynn F., Jones, Thomas K. , Levi, Daniel S. , Gray, Robert G. , Asnes, Jeremy D. , Cabalka, Allison K. , Fujimoto, Kazuto , Qureshi, Athar M. , Bergersen, Lisa, Haugan, Daniel, McElhinney, Doff B. , Asnes, Jeremy D , Benson, Lee N. , McElhinney, Doff B , Jones, Thomas K , Morray, Brian H , Cabalka, Allison , Bergersen, Lisa

Mayo Clinic

Circulation: Cardiovascular Interventions | July 16, 2025 | Volume: 18 | Issue: 9 | Pages: No page available

10.1161/circinterventions.125.015196 | PMID 40665900 Get It

BACKGROUND: The Harmony transcatheter pulmonary valve (TPV) is designed to treat severe pulmonary regurgitation in the native or surgically repaired right ventricular (RV) outflow tract. Early outcomes after TPV replacement with the Harmony valve have been positive, but longer-term data are limited. METHODS: The study included patients who received a commercially available TPV22 or TPV25 device as part of the nonrandomized, prospective Native Outflow Tract Early Feasibility Study, Harmony Pivotal Trial, and Continued Access Study. Patients completed at least 3 years of follow-up, and outcomes to 5 years were reported when available. RESULTS: Eighty-nine patients were catheterized, and 86 were successfully implanted with a Harmony TPV. Median duration of follow-up was 5 (range 0–6) years in the TPV22 group and 3 (1–4) years in the TPV25 group. At 3 years, all patients with a TPV22 and 96% of those with a TPV25 had ≤mild pulmonary regurgitation. By magnetic resonance imaging, significant improvements from preimplant to 2 years were observed in RV end-diastolic volume index, RV to left ventricular end-diastolic volume ratio, and effective RV stroke volume (all P <0.001). SF-36 quality-of-life scores improved after Harmony implantation and were sustained over 3 years. Early cases of ventricular tachycardia resolved, and there were no new arrhythmias. Adverse events up to 5 years included 3 deaths unrelated to the device or procedure, 2 cases of endocarditis that were treated (1 medically, 1 transcatheter debulking of a vegetation) and resolved, 6 patients with RV outflow tract obstruction or thrombosis resulting in valve-in valve procedures, and 1 major stent fracture resulting in surgical explant. CONCLUSIONS: At 3 to 5 years, Harmony TPV replacement resulted in sustained valve competence, beneficial cardiac remodeling, and improved quality of life. Continued monitoring is needed to assess long-term outcomes and valve performance. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01762124; NCT02979587.
Baseline predictors of poor clinical outcome despite recanalization of distal middle cerebral artery occlusions
Chafai, Imene , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Yedavalli, Vivek , Tjoumakaris, Stavropoula , Henninger, Nils , Nedelcu, Simona , Sundararajan, Sri Hari , Kühn, Anna Luisa , Khalife, Jane , Tan, Benjamin Yong‐Qiang , Heit, Jeremy J. , Regenhardt, Robert W. , Puri, Ajit S , Dyzmann, Christian , Filipe, João Pedro , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Patel, Aman B. , Wang, Maud , Lubicz, Boris , Guenego, Adrien , ##, On behalf of the MAD MT Investigators, Tjoumakaris, Stavropoula , Ghozy, Sherief , Scarcia, Luca , Tan, Benjamin Yq , Heit, Jeremy J , Regenhardt, Robert W , Cancelliere, Nicole M , Bernstock, Joshua D , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Essibayi, Muhammed Amir , Colasurdo, Marco , Marnat, Gaultier , Renieri, Leonardo , Filipe, João Pedro , Harker, Pablo , Alexandru Radu, Răzvan , Marotta, Thomas R , Spears, Julian , Ota, Takahiro , Mowla, Ashkan , Jabbour, Pascal , Clarençon, Frédéric , Nguyen, Thanh N , Varela, Ricardo , Altschul, David J , Gonzalez, Nestor R , Möhlenbruch, Markus A , Gory, Benjamin , Stracke, Paul , Hecker, Constantin , Shaikh, Hamza A , Liebeskind, David S. , Pedicelli, Alessandro , Alexandre, Andrea M , Tancredi, Illario , Faizy, Tobias D , Kalsoum, Erwah , Fahed, Robert , Wang, Maud , Mendes Pereira, Vitor , Lubicz, Boris , Dmytriw, Adam A , Guenego, Adrien , Kühn, Anna Luisa , Musmar, Basel , Salim, Hamza , Yedavalli, Vivek S , Henninger, Nils , Nedelcu, Simona , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Essibayi, Muhammed Amir , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Mowla, Ashkan , Jabbour, Pascal , Nguyen, Thanh N. , Baker, Amanda, Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Fahed, Robert , Dmytriw, Adam A. , ##, On behalf of the MAD MT Investigators

Mayo Clinic

Interventional Neuroradiology | July 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251342841 | PMID 40665742 Get It

Objective Mechanical thrombectomy (MT) is well-established for the treatment of acute ischemic stroke (AIS) from large vessel occlusion (LVO), with growing data supporting the expansion to distal and medium vessel occlusions (DMVO). Despite successful recanalization in DMVO, certain patients still experience poor long-term clinical outcomes, prompting our study to comprehensively explore pre-MT factors influencing outcome despite excellent recanalization (final modified Thrombolysis in Cerebral Infarction [mTICI] score ≥2c). Methods We retrospectively examined data from patients who consecutively underwent MT for a primary middle cerebral artery (MCA) DMVO across 37 centers in North America, Asia, and Europe. We identified baseline clinical and imaging factors associated with poor clinical outcome (defined as a modified Rankin Scale [mRS] score of 3–6) at 3 months, despite excellent recanalization using a multivariable model. Results Between September 2017 and July 2021, 623 patients achieved mTICI > 2b and they were included in our study. Among them, 198 (32%) experienced a poor clinical outcome (mRS 3–6). Predictors of poor clinical outcome included higher age (OR 1.05 [1.03–1.07], p < 0.001), higher NIHSS at admission (OR 1.12 [1.08–1.15], p < 0.001), higher baseline mRS (OR 1.77 [0.96–3.26], p = 0.067), and diabetes (OR 1.59 [1.01–2.48], p = 0.044). Higher ASPECTS was associated with a decreased risk of poor clinical outcome (OR 0.82 [0.71–0.94], p = 0.006). Conclusion Older age, diabetes, higher baseline mRS, and NIHSS were associated with poor clinical outcome in MCA DMVO despite excellent recanalization. Conversely, a higher ASPECTS decreased the probability of such an outcome.
An Exploratory Investigation into the Influence of Nasopharyngoscopy Findings on VPI Surgery Selection
Chee-Williams, Jessica L. , Perry, Jamie L. , Bunton, Kate , Sitzman, Thomas J. , Sitzman, Thomas J , Chee-Williams, Jessica L , Perry, Jamie L

Mayo Clinic

The Cleft Palate Craniofacial Journal | July 16, 2025 | Volume: 63 | Issue: 7 | Pages: 1999-2007

10.1177/10556656251359180 | PMID 40665693 Get It

Objective To explore if observations on nasopharyngoscopy influence the surgical procedure selected for the management of velopharyngeal insufficiency (VPI). Design Cross-sectional survey. Participants Seventeen surgeons with experience treating VPI. Interventions Review of twenty-four nasopharyngoscopy videos with a combination of velopharyngeal closure patterns and gap sizes. Main Outcome Measures Surgical procedure was selected after watching a nasopharyngoscopy video. Chi-square tests were used to evaluate if, for each surgeon, procedure selection varied based on closure pattern and gap size combination. Variable importance scores were obtained from a random forest analysis to quantify contribution of nasopharyngoscopy observations on procedure selection. Results Four procedures accounted for 86% of all surgeries selected: Furlow double-opposing Z-Plasty (33%), palatal lengthening using buccal myomucosal flaps (20%), pharyngeal flap (19%), and sphincter pharyngoplasty (14%). Four surgeons (23.5%) significantly varied their surgical selection when different closure pattern and gap size combinations were shown on nasopharyngoscopy. Ten surgeons (58%) selected the same procedure in ≥ 50% of the 24 nasopharyngoscopy videos. Individual surgeon preference was the strongest predictor of surgical selection, accounting for 57.9% of surgical selection variance. Velopharyngeal gap size accounted for 36.5% of the variance in surgical selection, yet the specific surgeries selected based on gap size varied widely across surgeons. Closure pattern was a weak predictor, contributing 5.6% to surgical selection variance. Conclusions Nasopharyngoscopy findings influence VPI surgical procedure selection in a highly individualized, surgeon-specific manner. Among factors observed on nasopharyngoscopy, velopharyngeal gap size has a much larger influence on procedure selection than closure pattern.
SAR Consensus Recommendations for Defining Small Bowel Crohn Disease Strictures at CT and MR Enterography
Dillman, Jonathan R. , Fidler, Jeff L. , Anupindi, Sudha A. , Fulmer, Clifton G. , Gordon, Ilyssa O. , Bruining, David H. , Deepak, Parakkal , Abualruz, Abdul Rahman , Al-Hawary, Mahmoud M. , Altinmakas, Emre , Guglielmo, Flavius F. , Jaffe, Tracy A. , Rieder, Florian , Baker, Mark E. , Dane, Bari , Dillman, Jonathan R , Fidler, Jeff L. , Anupindi, Sudha A , Fulmer, Clifton , Gordon, Ilyssa O , Bruining, David Henry , Deepak, Parakkal , Abualruz, Abdul-Rahman , Al-Hawary, Mahmoud , Guglielmo, Flavius F , Jaffe, Tracy , Bettenworth, Dominik , Rieder, Florian , Fletcher, Joel G , Baker, Mark E , Rimola, Jordi , Fletcher, Joel G.

Mayo Clinic

Radiology | July 15, 2025 | Volume: 316 | Issue: 1 | Pages: No page available

10.1148/radiol.243123 | PMID 40662968 Get It

This consensus by the Society of Abdominal Radiology Inflammatory Bowel Disease Disease Focused Panel provides an updated imaging-based definition of small bowel Crohn disease stricture for CT and MR enterography.
Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report
Al‐Samkari, Hanny , Kasthuri, Raj S. , Mager, Hans‐Jurgen, Zhou, Jenny Y. , Serra, Marcelo M. , Samuelson‐Bannow, Bethany T., Doren, Layla N Van , Piccirillo, Jay F. , Clancy, Marianne S. , Thomas, Sonia , Riera‐Mestre, Antoni , Gossage, James R. , Hermans, Cédric , Hammill, Adrienne M. , Drygalski, Annette von , Olitsky, Scott E., Faughnan, Marie E. , Sewaralthahab, Sarah , Iyer, Vivek N , Al-Samkari, Hanny , Hammill, Adrienne , Kasthuri, Raj S , Thomas, Sonia M , McCrae, Keith R. , Pishko, Allyson M. , Iyer, Vivek , Winship, Ingrid , Mei‐Zahav, Meir

Mayo Clinic

American Journal of Hematology | July 15, 2025 | Volume: 100 | Issue: 10 | Pages: 1813-1827

10.1002/ajh.70011 | PMID 40662351 Get It

ABSTRACT Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT‐specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician‐investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. Search Strategy and Selection Criteria Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4–13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.
Preserving noise texture through training data curation for deep learning denoising of high‐resolution cardiac EID‐CT
Treb, Kevin , Chang, Shaojie , Koons, Emily K. , Marsh, Jeffrey F., Foley, Thomas A. , Williamson, Eric E. , Koons, Emily, Marsh, Jeffrey, Foley, Thomas , McCollough, Cynthia, Treb, Kevin , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Medical Physics | July 15, 2025 | Volume: 52 | Issue: 7 | Pages: No page available

10.1002/mp.17938 | PMID 40660962 Get It

Abstract Background To utilize high spatial resolution reconstructions for cardiac imaging at energy‐integrating detector CT (EID)‐CT with comparable noise to similar reconstructions at photon‐counting detector (PCD)‐CT, methods to control EID‐CT image noise are needed. Supervised convolutional neural networks (CNN) have shown promise for denoising, but a challenge remains to efficiently create high‐quality and unbiased estimates of noise without access to dedicated software or proprietary information, such that natural noise texture is retained in CNN‐denoised CT images. Purpose This study aims to develop and test image‐based noise estimation methods that can be used to train a CNN model, and to evaluate denoising performance and noise texture preservation for EID‐CT coronary CT angiography (cCTA) images reconstructed with high‐resolution kernels. Methods U‐net CNN models were trained for denoising. To supervise training, noise‐only images were estimated directly from high‐resolution kernel (Bv59) reconstructed EID‐CT (HR EID‐CT) patient images using two different methods: subtraction of low‐ and high‐strength iterative reconstruction (IR); subtraction of adjacent image slices with the same IR strength. The noise estimates from these methods contain differing noise texture and anatomical information. Networks were trained and validated separately for three data sets: the training data from each of the two noise‐estimation methods, and a 50%–50% partition of training data between the two methods. The trained models were applied to two sets of testing data: CT images of a uniform water phantom to measure noise power spectra (NPS), and an independent cohort of seven patient cCTA HR EID‐CT exams. The denoised patient images were compared to standard resolution EID‐CT reconstructions (Bv40). As a low‐noise reference, patient images acquired on the same day with a PCD‐CT and reconstructed using a similar kernel as HR EID‐CT were used for comparison. Results Models trained with each noise‐image estimation method denoised the HR EID‐CT images by 74%–79% to achieve a comparable noise magnitude to the HR PCD‐CT images. The peak, average, and 10% peak frequencies of the NPS of the input images (6.08, 6.24, and 12.0 cm −1 ) were better approximated by the model trained on adjacent slice subtraction (6.56, 5.87, and 11.5 cm −1 ) than by the model trained on subtraction of low‐ and high‐IR images (4.64, 5.44, and 11.3 cm −1 ). In cCTA images, the IR subtraction model images retained anatomic structures from input images but resulted in undesirable salt‐and‐pepper noise texture and CT number bias. The model trained on adjacent slice subtraction images had more natural texture and no significant bias, but the model sometimes removed small anatomic structures. The model trained on the mixed training dataset preserved both noise texture and anatomy from the model inputs and enabled visualization of small structures seen in PCD‐CT images that were previously unresolved by EID‐CT. Conclusions The noise texture and anatomical accuracy in CT images denoised with an image‐based supervised CNN are greatly influenced by the characteristics and partitioning of training data. With higher‐resolution reconstructions and noise texture‐preserving deep learning denoising, the quality of cCTA images from EID‐CT can be enhanced to enable resolvability of subtle anatomy similar to PCD‐CT.
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
Chen, Charles D., Jack, Clifford R. , Koeppe, Robert, Hornbeck, Russ C. , Koudelis, Deborah, Keefe, Sarah , Aggarwal, Neelum T. , Bird, Thomas D. , Black, Sandra E., Chhatwal, Jasmeer P. , Day, Gregory S. , Farlow, Martin R. , Gauthier, Serge , Honig, Lawrence S., Xiong, Chengjie , Masellis, Mario, Méndez, Patricio Chrem, Ringman, John M. , Snider, B. Joy, Salloway, Stephen, Dyck, Christopher H. van , Klein, Gregory , Clifford, David B. , Hassenstab, Jason , Mills, Susan L., Perrin, Richard J., Supnet, Charlene , Wang, Guoqiao , Xiong, Chengjie , Team, for the DIAN‐TU Study, Jack, Clifford R , Day, Gregory S , Xiong, Chengjie , Chen, Charles D , Hassenstab, Jason , Supnet-Bell, Charlene , McCullough, Austin , Gordon, Brian A. , Joseph‐Mathurin, Nelly , McKay, Nicole S. , Hobbs, Diana A. , Flores, Shaney , Allegri, Ricardo , Berman, Sarah , Black, Sandra E. , Brooks, William S. , Fox, Nick C. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jucker, Mathias , Masters, Colin L. , Schofield, Peter R. , Shimada, Hiroyuki , Suzuki, Kazushi , Cruchaga, Carlos , Li, Yan , McDade, Eric , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Team, for the DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | July 15, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70347 | PMID 40660741 Get It

Abstract INTRODUCTION Monoclonal anti‐amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD). METHODS In the DIAN‐TU‐001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [ 11 C]‐Pittsburgh compound‐B (PiB) positron emission tomography (PET), [ 18 F]‐fluoro‐2‐deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI). RESULTS Gantenerumab significantly reduced PiB‐PET uptake overall and in most regions and showed no changes in FDG‐PET or MRI measures. Drug effects were associated with baseline PiB‐PET uptake, and the largest effects occurred in medial regions. DISCUSSION Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB‐PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design. Highlights Gantenerumab unevenly decreased Aβ burden as measured by PiB‐PET across brain regions. The strongest decrease in PiB‐PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG‐PET metabolism or MRI volumetrics after 4 years.
Spectrum of Interstitial Cell of Cajal Deficits in Chronic Gastroduodenal Disorders: Systematic Review and Meta-Analysis
Varghese, Chris , Pasricha, Pankaj J. , Parkman, Henry P. , Andrews, Christopher N. , Farrugia, Gianrico , O’Grady, Gregory , Parkman, H P , Andrews, Christopher N , Keszthelyi, Daniel , Gharibans, Armen A , Farrugia, Gianrico , O'Grady, Gregory , Varghese, Chris , Abell, Thomas L. , Gharibans, Armen A.

Mayo Clinic

American Journal of Gastroenterology | July 14, 2025 | Volume: 121 | Issue: 1 | Pages: 112-121

10.14309/ajg.0000000000003646 | PMID 40658171 Get It

INTRODUCTION: Chronic neurogastroduodenal disorders are heterogeneous and thought to lie on a spectrum of disease encompassing both sensory and neuromuscular pathologies. Abnormalities of interstitial cells of Cajal (ICC), a subset of which generate pacemaker signals and subsequently motility, have been implicated in their pathophysiology. We systematically reviewed the literature to pool ICC deficits observed in chronic neurogastroduodenal disorders. METHODS: Studies quantifying gastric ICC from the corpus or antrum, in adult patients with gastroparesis, functional dyspepsia (FD), or chronic nausea and vomiting syndromes (CNVS) were analyzed (PROSPERO: CRD42024613226). MEDLINE, Embase and CENTRAL databases were searched systematically. Random effects meta-analyses were used to compare ICC counts by disorder group with subgroup analysis by quantification methodology. RESULTS: Overall, 2,158 studies were screened and 22 included. Comparative studies (n = 12) showed patients with chronic neurogastroduodenal disorders (n = 167 with gastroparesis, n = 19 with FD ± CNVS) had lower ICC counts than nondiabetic controls (n = 130); standardized mean difference −1.58, 95% confidence interval −2.09 to −1.07, P < 0.0001, with more severe deficits in gastroparesis compared to FD ± CNVS (standardized mean difference [SMD] −0.44, P = 0.048). A spectrum of ICC deficits was evident in a subgroup of studies using gold-standard methods with c-KIT antibody and 4',6-diamidino-2-phenylindole-stained nuclei confirmation (7 studies, 246 patients: mean ICC counts 2.29 in gastroparesis vs 3.49 in FD ± CNVS, and 5.27 in controls; P < 0.001 all comparisons). Most studies were at high risk of bias (n = 21). DISCUSSION: Marked depletion of ICC is a consistent finding in neurogastroduodenal disorders. A spectrum of disease is revealed, with greater depletion associated with delayed emptying. Techniques for clinically defining ICC-driven gastric neuromuscular dysfunction should be prioritized.
Enhancing proton therapy quality assurance with custom‐designed Octopoint phantom and Gafchromic film
Tang, Xueyan , Beltran, Chris , Furutani, Keith M. , Gilson, Glen, Gustafson, Jon M., Herman, Michael , Johnson, J. , Kruse, Jon J. , Long, Kenneth M., Mundy, Daniel W. , Remmes, Nicholas B. , Tasson, A , Whitaker, Todd , Matysiak, Witold, Tryggestad, E., Matysiak, W , Gilson, Graham S, Gustafson, Jon, Ito, Shima, Johnson, Jed E , Tasson, Alexandria , Whitaker, Thomas J , Tryggestad, Erik J, Beltran, Chris J , Furutani, Keith M , Matysiak, Witold P , Ito, Shima , Long, Kenneth M.

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 14, 2025 | Volume: 26 | Issue: 7 | Pages: No page available

10.1002/acm2.70156 | PMID 40657664 Get It

Abstract Background Proton therapy offers precise tumor targeting while minimizing damage to surrounding healthy tissue, making it especially valuable for treating tumors near critical organs and in pediatric patients. However, its success depends on accurate beam delivery, requiring rigorous quality assurance (QA) to maintain treatment precision and effectiveness. Purpose This study aims to standardize the measurement of key aspects of proton therapy delivery, such as gantry and couch isocentricity, spot position accuracy, and spot size consistency. The goal is to enhance the delivery accuracy of proton therapy across various clinical settings, improving patient outcomes. Methods The QA framework uses the Octopoint phantom, Gafchromic film, and spot position monitor (SPM) log data to evaluate proton beam isocentricity, spot position, and spot size. The Octopoint phantom, made from acrylic, was used with Gafchromic films at various gantry and couch angles to measure isocentricity. MATLAB tools were used to analyze spot positions, and SPM logs provided verification. Sensitivity tests were conducted to assess the system's response to intentional shifts and errors, ensuring alignment with clinical QA standards. Results The Octopoint phantom's stepwise two‐dimensional (2D) fitting process, validated against film‐measured dose profiles, accurately identified beam and ball bearing (BB) centroid locations. Isocentricity tests conducted over 8 months across four gantries demonstrated consistent beam‐to‐BB radial offsets. The phantom showed excellent repeatability, with a maximum standard deviation of 0.1 mm across various couch‐gantry combinations. Sensitivity testing across all axes revealed a strong alignment between intended shifts and measured values. Over the course of a year, film measurements tracked spot position and size consistency, with deviations remaining within acceptable clinical limits. Comparisons with SPM data further confirmed the system's reliability in maintaining beam accuracy across different gantry angles and energy levels. Conclusions This study presents a reliable QA framework for ensuring precision in proton therapy delivery. By combining the Octopoint phantom, Gafchromic film analysis, and SPM log file evaluation, we effectively measured isocentricity, spot position accuracy, and spot size stability. The framework demonstrated adaptability across various clinical QA tasks, enhancing the accuracy and safety of proton therapy treatments.